scholarly journals TRAF3IP2 (TRAF3 Interacting Protein 2) Mediates Obesity-Associated Vascular Insulin Resistance and Dysfunction in Male Mice

Hypertension ◽  
2020 ◽  
Vol 76 (4) ◽  
pp. 1319-1329
Author(s):  
Zachary I. Grunewald ◽  
Francisco I. Ramirez-Perez ◽  
Makenzie L. Woodford ◽  
Mariana Morales-Quinones ◽  
Salvador Mejia ◽  
...  

Insulin resistance in the vasculature is a characteristic feature of obesity and contributes to the pathogenesis of vascular dysfunction and disease. However, the molecular mechanisms underlying obesity-associated vascular insulin resistance and dysfunction remain poorly understood. We hypothesized that TRAF3IP2 (TRAF3 interacting protein 2), a proinflammatory adaptor molecule known to activate pathological stress pathways and implicated in cardiovascular diseases, plays a causal role in obesity-associated vascular insulin resistance and dysfunction. We tested this hypothesis by employing genetic-manipulation in endothelial cells in vitro, in isolated arteries ex vivo, and diet-induced obesity in a mouse model of TRAF3IP2 ablation in vivo. We show that ectopic expression of TRAF3IP2 blunts insulin signaling in endothelial cells and diminishes endothelium-dependent vasorelaxation in isolated aortic rings. Further, 16 weeks of high fat/high sucrose feeding impaired glucose tolerance, aortic insulin-induced vasorelaxation, and hindlimb postocclusive reactive hyperemia, while increasing blood pressure and arterial stiffness in wild-type male mice. Notably, TRAF3IP2 ablation protected mice from such high fat/high sucrose feeding-induced metabolic and vascular defects. Interestingly, wild-type female mice expressed markedly reduced levels of TRAF3IP2 mRNA independent of diet and were protected against high fat/high sucrose diet-induced vascular dysfunction. These data indicate that TRAF3IP2 plays a causal role in vascular insulin resistance and dysfunction. Specifically, the present findings highlight a sexual dimorphic role of TRAF3IP2 in vascular control and identify it as a promising therapeutic target in vasculometabolic derangements associated with obesity, particularly in males.

2016 ◽  
Vol 310 (8) ◽  
pp. E662-E675 ◽  
Author(s):  
Yu Yasutake ◽  
Akiko Mizokami ◽  
Tomoyo Kawakubo-Yasukochi ◽  
Sakura Chishaki ◽  
Ichiro Takahashi ◽  
...  

Uncarboxylated osteocalcin (GluOC), a bone-derived hormone, regulates energy metabolism by stimulating insulin secretion, pancreatic β-cell proliferation, and adiponectin expression in adipocytes. Previously, we showed that long-term intermittent or daily oral administration of GluOC reduced the fasting blood glucose level, improved glucose tolerance, and increased the fasting serum insulin concentration as well as pancreatic β-cell area in female mice fed a normal or high-fat, high-sucrose diet. We have now performed similar experiments with male mice and found that such GluOC administration induced glucose intolerance, insulin resistance, and adipocyte hypertrophy in those fed a high-fat, high-sucrose diet. In addition, GluOC increased the circulating concentration of testosterone and reduced that of adiponectin in such mice. These phenotypes were not observed in male mice fed a high-fat, high-sucrose diet after orchidectomy, but they were apparent in orchidectomized male mice or intact female mice that were fed such a diet and subjected to continuous testosterone supplementation. Our results thus reveal a sex difference in the effects of GluOC on glucose homeostasis. Given that oral administration of GluOC has been considered a potentially safe and convenient option for the treatment or prevention of metabolic disorders, this sex difference will need to be taken into account in further investigations.


AGE ◽  
2015 ◽  
Vol 37 (3) ◽  
Author(s):  
Cristal M. Hill ◽  
Oge Arum ◽  
Ravneet K. Boparai ◽  
Feiya Wang ◽  
Yimin Fang ◽  
...  

2020 ◽  
Vol 34 (S1) ◽  
pp. 1-1
Author(s):  
Christopher J. Oldfield ◽  
Teri L. Moffatt ◽  
Kimberley A. O'Hara ◽  
Bo Xiang ◽  
Vernon W. Dolinsky ◽  
...  

1997 ◽  
Vol 272 (5) ◽  
pp. R1571-R1576 ◽  
Author(s):  
T. J. Horton ◽  
E. C. Gayles ◽  
P. A. Prach ◽  
T. A. Koppenhafer ◽  
M. J. Pagliassotti

In male rats, 2 wk of high-sucrose feeding results in insulin resistance and hypertriglyceridemia [Pagliassotti, M.J., P.A. Prach, T.A. Koppenhafer, and D.A. Pan. Am. J. Physiol. 271 (Regulatory Integrative Comp. Physiol. 40): R1319-R1326, 1996]. The present study aimed to determine if female rats also become insulin resistant and hypertriglyceridemic in response to high-sucrose feeding. Female Wistar rats (7 wk old) were fed either a high-sucrose diet (68% energy) (SU) or a high-starch diet (68% energy) (ST) for 3, 5, or 8 wk. In each animal, glucose kinetics were measured using [3-(3)H]glucose under basal and hyperinsulinemic conditions (insulin infusion 4.0 mU.kg-1.min-1). Body weight and basal glucose kinetics were not different between diet groups at 3, 5, or 8 wk. Glucose infusion rate (mg.kg-1.min-1) was not different between groups (3 wk: 17.7 +/- 1.6 ST, 16.6 +/- 0.9 SU; 5 wk: 16.1 +/- 0.9 ST, 15.1 +/- 2.0 SU; 8 wk: 18.3 +/- 1.9 ST, 16.1 +/- 1.5 SU). Clamp rate of glucose appearance (mg.kg-1.min-1) was also not different between diet groups (3 wk: 4.0 +/- 1.6 ST, 3.6 +/- 1.4 SU; 5 wk: 2.6 +/- 1.0 ST, 2.3 +/- 1.14 SU; 8 wk: 5.9 +/- 1.8 ST, 7.7 +/- 1.2 SU). No difference was observed in plasma and tissue triglycerides or tissue glycogen between sucrose- and starch-fed animals. We therefore conclude that female rats, in contrast to males, do not develop sucrose-induced insulin resistance and hypertriglyceridemia.


2009 ◽  
Vol 28 (6) ◽  
pp. 627-635 ◽  
Author(s):  
Arrate Lasa ◽  
Itziar Churruca ◽  
Edurne Simón ◽  
María Teresa Macarulla ◽  
Alfredo Fernández-Quintela ◽  
...  

2020 ◽  
Author(s):  
◽  
Zachary I. Grunewald

[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI-COLUMBIA AT REQUEST OF AUTHOR.] Insulin resistance in the vasculature is a characteristic feature of obesity and contributes to the pathogenesis of vascular dysfunction and disease. However, the molecular mechanisms underlying obesity-associated vascular insulin resistance and dysfunction remain poorly understood. We hypothesized that TRAF3 Interacting Protein 2 (TRAF3IP2), a pro-inflammatory adaptor molecule known to activate pathological stress pathways and implicated in cardiovascular disease, plays a causal role in obesity-associated vascular insulin resistance and dysfunction. We tested this hypothesis by employing genetic-manipulation in endothelial cells in vitro and in isolated arteries ex vivo, and by using a mouse model of TRAF3IP2 ablation and diet-induced obesity in vivo. We show that forced expression of TRAF3IP2 blunts insulin signaling in endothelial cells and diminishes endothelium-dependent vasorelaxation in isolated aortic rings. Further, 16 weeks of high fructose/high sucrose (HFHS) feeding impaired glucose tolerance, aortic insulin-induced vasorelaxation, and hindlimb postocclusive reactive hyperemia, while increasing blood pressure and arterial stiffness in wild-type male mice. Notably, TRAF3IP2 gene ablation protected mice against such metabolic and vascular defects caused by HFHS feeding. Interestingly, wild-type female mice expressed markedly reduced levels of TRAF3IP2 mRNA independent of diet and were protected against HFHS diet-induced vascular dysfunction. These data indicate that TRAF3IP2 plays a causal role in vascular insulin resistance and dysfunction. Specifically, the present findings highlight a sexual dimorphic role of TRAF3IP2 in vascular control and identify it as a promising therapeutic target in vasculometabolic derangements associated with obesity, particularly in males.


Sign in / Sign up

Export Citation Format

Share Document